5WLX

Solution structure of kappa-theraphotoxin-Aa1a


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 20 
  • Selection Criteria: Best stereochemical properties as judged by Molprobity 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Novel venom-derived inhibitors of the human EAG channel, a putative antiepileptic drug target.

Ma, L.Chin, Y.K.Y.Dekan, Z.Herzig, V.Chow, C.Y.Heighway, J.Lam, S.W.Guillemin, G.J.Alewood, P.F.King, G.F.

(2018) Biochem. Pharmacol. 158: 60-72

  • DOI: 10.1016/j.bcp.2018.08.038

  • PubMed Abstract: 
  • Recently, we and other groups revealed that gain-of-function mutations in the human ether à go-go voltage-gated potassium channel hEAG1 (K <sub>v </sub>10.1) lead to developmental disorders with associated infantile-onset epilepsy. However, the physi ...

    Recently, we and other groups revealed that gain-of-function mutations in the human ether à go-go voltage-gated potassium channel hEAG1 (K v 10.1) lead to developmental disorders with associated infantile-onset epilepsy. However, the physiological role of hEAG1 in the central nervous system remains elusive. Potent and selective antagonists of hEAG1 are therefore much sought after, both as pharmacological tools for studying the (patho)physiological functions of this enigmatic channel and as potential leads for development of anti-epileptic drugs. Since animal venoms are a rich source of potent ion channel modifiers that have been finely tuned by millions of year of evolution, we screened 108 arachnid venoms for hEAG1 inhibitors using electrophysiology. Two hit peptides (Aa1a and Ap1a) were isolated, sequenced, and chemically synthesised for structure-function studies. Both of these hEAG1 inhibitors are C-terminally amidated peptides containing an inhibitor cystine knot motif, which provides them with exceptional stability in both plasma and cerebrospinal fluid. Aa1a and Ap1a are the most potent peptidic inhibitors of hEAG1 reported to date, and they present a novel mode of action by targeting both the activation and inactivation gating of the channel. These peptides should be useful pharmacological tools for probing hEAG1 function as well as informative leads for the development of novel anti-epileptic drugs.


    Organizational Affiliation

    Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia. Electronic address: linlin.ma@flinders.edu.au.,Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.,Department of Biomedical Sciences, Macquarie University, Sydney, NSW 2109, Australia; St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW 2010, Australia.,Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia. Electronic address: glenn.king@imb.uq.edu.au.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Kappa-theraphotoxin-Aa1a
A
37Avicularia aurantiacaMutation(s): 0 
Find proteins for A0A3F2YLP5 (Avicularia aurantiaca)
Go to UniProtKB:  A0A3F2YLP5
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
NH2
Query on NH2
A
NON-POLYMERH2 N

--

Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 20 
  • Selection Criteria: Best stereochemical properties as judged by Molprobity 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-08-01
    Type: Initial release
  • Version 1.1: 2019-02-27
    Type: Data collection, Database references